Shaunak Kulkarni, MD
Article
Anti-Xa Monitoring During Therapeutic LMWH Use Leads to Frequent Dose Changes Without Clear Evidence of Improved Clinical Outcomes
September 2, 2026
Clinical Question: In patients receiving therapeutic low-molecular-weight heparin (LMWH), does anti-Xa monitoring with subsequent dose adjustment improve bleeding or thrombotic outcomes? Background:...